Journal
AMERICAN JOURNAL OF PSYCHIATRY
Volume 168, Issue 6, Pages 593-602Publisher
AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/appi.ajp.2010.10010032
Keywords
-
Categories
Funding
- NIMH [R01M H063852, N01 MH90003, K02 M H66249]
- NIDA
- CDC
- Aspect Medical Systems
- Eli Lilly
- PamLab
- Pfizer
- Agency for Healthcare Research and Quality (AHRQ)
- Corcept Therapeutics
- Cyberonics
- Merck
- National Institute on Drug Abuse
- Novartis
- Pharmacia Upjohn
- Predix EPIX Pharmaceuticals
- Solvay Pharmaceuticals
- Targacept
- Abbott Laboratories
- Abdi Ibrahim
- Akzo (Organon Pharmaceuticals)
- AstraZeneca
- Bristol-Myers Squibb
- Cephalon, Evotec
- Fabre Kramer Pharmaceuticals
- Forest Pharmaceuticals
- GlaxoSmithKline
- Janssen Pharmaceutica Products
- Johnson Johnson PRD
- Meade Johnson
- Medtronic
- Neuronetics
- Otsuka Pharmaceuticals
- Parke-Davis Pharmaceuticals
- Sepracor
- SHIRE Development
- VantagePoint
- Wyeth-Ayerst Laboratories
- Cephalon
- Alkermes
- BrainCells
- CeNeRx BioPharma
- Clinical Trials Solutions
- Euthymics Bioscience
- i3 Innovus/Ingenix
- Lorex Pharmaceuticals
- Pharmavite
- Roche
- RCT Logic
- Sanofi-Aventis US
- Synthelabo
- BioResearch
- Clintara
- Covidien
- EnVivo Pharmaceuticals
- Ganeden Biotech
- Icon Clinical ResearchLichtwer Pharma GmbH
- NARSAD
- NCCAM
- Photothera
- Shire
- Affectis Pharmaceuticals AG
- Amarin Pharma
- Auspex Pharmaceuticals
- Bayer AG
- Best Practice Project Management
- BioMarin Pharmaceuticals
- Biovail Corporation
- CNS Response
- Compellis Pharmaceuticals
- Cypress Pharmaceutical
- DiagnoSearch Life Sciences
- Dinippon Sumitomo Pharma
- Dov Pharmaceuticals
- Edgemont Pharmaceuticals
- Eisai Inc.
- ePharmaSolutions
- EPIX Pharmaceuticals
- Fabre-Kramer Pharmaceuticals
- GenOmind
- Grunenthal GmbH
- Janssen Pharmaceutica
- Jazz Pharmaceuticals
- Knoll Pharmaceuticals
- Labopharm
- Lundbeck
- MedAvante
- MSI Methylation Sciences
- Naurex
- NextWave Pharmaceuticals
- Nutrition 21
- Orexigen Therapeutics
- PharmaStar
- PharmoRx Therapeutics
- Precision Human Biolaboratory
- Prexa Pharmaceuticals
- Puretech Ventures
- PsychoGenics
- Psylin Neurosciences
- Rexahn Pharmaceuticals
- Ridge Diagnostics
- Servier Laboratories
- Schering-Plough Corporation
- Somaxon Pharmaceuticals
- Somerset Pharmaceuticals
- Sunovion Pharmaceuticals
- Takeda Pharmaceutical Company Limited
- Tal Medical
- Tetragenex Pharmaceuticals
- TransForm Pharmaceuticals
- Transcept Pharmaceuticals
- Vanda Pharmaceuticals
- Adamed
- Advanced Meeting Partners
- American Psychiatric Association
- American Society of Clinical Psychopharmacology
- Belvoir Media Group
- Boehringer Ingelheim GmbH
- CME Institute/Physicians Postgraduate Press
- Imedex
- MGH Psychiatry Academy/Primedia
- MGH Psychiatry Academy/Reed Elsevier
- United BioSource
- Advanced Neuromodulation Systems
- Brain Resource
- Bristol-Myers Squibb/Otsuka
- Gerson Lehrman Group
- Magellan Health Services
- Merck Company
- Novartis Pharmaceuticals
- Ono Pharmaceuticals
- Organon
- University of Michigan
- Urban Institute
- Wyeth Ayerst
- Forest Laboratories
- Otsuka
- Stanley Medical Research Institute
- ImaRx Therapeutics
- Bristol-Myers Squibb Company
- Case-Western University
- Singapore Clinical Research Institute
- Dey Pharmaceuticals
- Venebio
- Dey
Ask authors/readers for more resources
Objective: Maternal major depressive disorder is an established risk factor for child psychopathology. The authors previously reported that 1 year after initiation of treatment for maternal depression, children of mothers whose depression remitted had significantly improved functioning and psychiatric symptoms. This study extends these findings by examining changes in psychiatric symptoms, behavioral problems, and functioning among children of depressed mothers during the first year after the mothers' remission from depression. Method: Children were assessed at baseline and at 3-month intervals with the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version, the Child Behavior Checklist, and the Children's Global Assessment Scale for 1 year after their mothers' remission or for 2 years if the mothers did not remit. The authors compared children of early remitters (0-3 months; N=36), late remitters (3-12 months; N=28), and nonremitters (N=16). Results: During the postremission year, children of early-remitting mothers showed significant improvement on all outcomes. Externalizing behavioral problems decreased in children of early-and late-remitting mothers but increased in children of nonremitting mothers. Psychiatric symptoms decreased significantly only in children of mothers who remitted, and functioning improved only in children of early-remitting mothers. Conclusions: Remission of mothers' depression, regardless of its timing, appears to be related to decreases in problem behaviors and symptoms in their children over the year after remission. The favorable effect of mothers' remission on children's functioning was observed only in children of early-remitting mothers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available